Advertisement

Product › Details
vaccine
![]() |
Next higher product group | pharmaceutical |
Status | 1998-01-01 sales existent | |
Record changed: 2022-04-25 |
Advertisement
![Picture [iito] Fighting Customers 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-fighting-customers.jpg)
More documents for vaccine
- [1] Valneva S.E.. (4/25/22). "Press Release: Valneva Provides Regulatory Update on its inactivated COVID-19 Vaccine Candidate". Saint-Herblain....
- [2] CureVac N.V.. (4/21/22). "Press Release: CureVac and GSK’s Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study". Tübingen & Boston, MA....
- [3] BioNTech SE. (4/11/22). "Press Release: BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines". Mainz & Beminster, NJ....
- [4] CureVac N.V.. (4/11/22). "Press Release: CureVac and GSK Enter into Pandemic Preparedness Contract with German Government". Tübingen & Boston, MA....
- [5] Catalent, Inc.. (4/6/22). "Press Release: Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe". Somers, NJ....
- [6] CureVac N.V.. (3/30/22). "Press Release: CureVac and GSK Start Clinical Development of Second-generation COVID-19 Vaccine Candidate, CV2CoV". Tübingen & Boston, MA....
- [7] Abera Bioscience AB. (3/29/22). "Press Release: Abera Bioscience Signs Agreement with NorthX Biologics for GMP Manufacturing"....
- [8] Bavarian Nordic A/S. (3/21/22). "Press Release: Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets...
- [9] Valneva S.E.. (2/21/22). "Press Release: Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development". Saint-Herblain....
- [10] BioNTech SE. (1/5/22). "Press Release: Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine". New York, NY & Mainz....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top